CRDL Stock Chart & Stats
$1.51
-$0.03(-2.19%)
At close: 4:00 PM EST
$1.51
-$0.03(-2.19%)
Day’s Range― - ―
52-Week Range$0.88 - $1.71
Previous Close$1.33
Volume248.87K
Average Volume (3M)701.45K
Market Cap
$124.21M
Enterprise Value$144.20M
Total Cash (Recent Filing)$27.67M
Total Debt (Recent Filing)$116.41K
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 17, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding115,272,240
10 Day Avg. Volume564,759
30 Day Avg. Volume701,452
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)6.37
Price to Sales (P/S)0.00
P/FCF Ratio-4.77
Enterprise Value/Market Cap1.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.85K
Enterprise Value/Ebitda-4.09
Forecast
1Y Price Target
$8.50Price Target Upside462.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low debt reduces refinancing and interest-rate vulnerability, preserving financial flexibility for a clinical-stage biotech. Over the next several months this lessens solvency risk and gives management optionality to prioritize R&D spending or negotiate financings from a position of lower fixed obligations.
Focused Clinical PipelineA focused pipeline addressing cardiovascular inflammation and heart-failure indications concentrates R&D efforts on large, unmet markets. Sustained progress in these specialty indications can create durable clinical and regulatory value if trials succeed, aligning long-term upside with clear therapeutic targets and differentiated cannabinoid formulations.
Narrowing Cash Outflows TrendObserved improvement in cash outflow trajectory implies management has begun moderating burn or improving efficiency. If sustained over 2–6 months, this trend lowers near-term financing pressure, extends runway to advance clinical milestones, and reduces the immediacy of dilutive capital raises while programs progress.
Bears Say
Pre-revenue StatusWith no commercial revenue, value depends entirely on successful clinical development and regulatory approval. This structural reliance on binary trial outcomes increases long-term execution risk, forces ongoing R&D spending without offsetting cash inflows, and delays durable revenue generation for an extended horizon.
Heavy Cash BurnSustained negative operating and free cash flow at this scale creates persistent financing needs. Over multiple quarters this amplifies dilution or debt reliance, constrains the ability to expand trials or invest in complementary programs, and raises the probability that financing timing, not science, will dictate development pacing.
Equity Erosion & Negative ROEDeclining equity and negative ROE reflect cumulative losses that weaken the balance sheet buffer. Structurally, this increases sensitivity to further losses and makes future equity raises more dilutive. Management may face trade-offs between conserving cash and advancing trials, which can prolong timelines or reduce program scope.
Cardiol Therapeutics News
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was $0.88 and its highest was $1.71 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is $124.21M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 43 days.
How were Cardiol Therapeutics’s earnings last quarter?
Currently, no data Available
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 115,272,240 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in CRDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiol Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (462.91% Upside)
$8.50 (462.91% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.1%
Last 30 Days ▼ 14.1%
Last 30 Days ▼ 14.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.90%
12-Months-Change
Fundamentals
Return on Equity
-229.16%
Trailing 12-Months
Asset Growth
27.24%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
CRDL Stock 12 Month Forecast
Average Price Target
$8.50
▲(462.91% Upside)
Technical Analysis
Bausch Health Companies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―
Ownership Overview
2.25% Insiders
0.05% Mutual Funds
0.09% Other Institutional Investors
96.85% Public Companies and
Individual Investors